The Globe and Mail reports in its Thursday, Dec. 21, edition that ATB Capital Markets analyst Frederico Gomes has reaffirmed his "outperform" recommendation for Organigram Holdings. The Globe's David Leeder writes that Mr. Gomes reduced his share target by $1 to $5.50. Analysts on average target the shares at $4.54. Mr. Gomes says in a note: "Given the material cash burn this quarter, we are wary of the longer-than-expected runway to turn FCF positive as the rec. market remains challenging while near-term catalysts appear limited. Considering the disappointing results and the enduring challenges faced by LPs, our model implies that Organigram would have to surprise on margins and/or benefit from working capital changes to meet its FCF guidance. However, we continue to see Organigram as a long-term winner among LPs given its liquidity position, and prospects for growth/margin expansion via new product introductions, efficiency investments (i.e., seed-based production, automation and capacity expansion), and Jupiter investment platform. We believe Organigram remains one of the best-positioned LPs due do its robust balance sheet ($155-million in pro forma net cash following the BAT investment)."